Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued access to darunavir/ritonavir for HIV-1 infected adults and children
2017-000285-30Phase 3
- Sponsor
- Johnson & Johnson
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of darunavir and ritonavir in Human immunodeficiency virus infection type 1, sponsored by Johnson & Johnson. Primary endpoints: Safety and tolerability assessments, Mortality and 3 more.
02
Drugs
darunavirritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2017-000285-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000285-30.